Monoclonal Antibodies in the Management of Rheumatoid Arthritis Prof. John D. Isaacs
|
|
- Clifford Marshall
- 6 years ago
- Views:
Transcription
1 John D Isaacs Professor of Clinical Rheumatology Director, Wilson Horne Immunotherapy Centre Newcastle University, UK 1 Rheumatoid arthritis Targeting T-cells Targeting B-cells Costimulation blockade Novel cytokine targets 2 3 The screen versions of these slides have full details of copyright and acknowledgements 1
2 Chronic inflammation of synovial membrane 1% prevalence in Western world Female preponderance (2-3:1) Peak onset in 5 th decade Genetic predisposition HLA-DRB1, PTPN22 Environmental triggers Smoking,?infectious, dietary, stress 4 Joint pain Joint swelling Early morning joint stiffness Fatigue Joint damage and deformity Impaired joint function and disability Extra-articular disease (nodules, lungs, vaculitis etc.) 5 BONE JOINT SPACE JOINT CAPSULE INFLAMED SYNOVIUM INVADING CARTILAGE AND BONE SYNOVIUM CARTILAGE BONE 6 The screen versions of these slides have full details of copyright and acknowledgements 2
3 Strong genetic linkage to HLA-DRB1 Lymphocytic infiltrate in synovium Circulating autoantibodies (rheumatoid factor, anti-ccp) Familial association with other autoimmune diseases (diabetes, thyroiditis etc.) 7 8 Panayi GS, Rheumatology 25;44 (S2):ii3-ii7 9 The screen versions of these slides have full details of copyright and acknowledgements 3
4 Control symptoms and signs Prevent joint damage Maintain function Maintain QOL Prevent secondary complications (e.g., ischaemic heart disease) 1 Rheumatoid arthritis Targeting T-cells Targeting B-cells Costimulation blockade Novel cytokine targets 11 Depleting therapies Non-depleting therapies FIRST ATTEMPTS AT THERAPEUTIC TOLERANCE IN HUMAN AUTOIMMUNITY 12 The screen versions of these slides have full details of copyright and acknowledgements 4
5 First humanised therapeutic antibody Human IgG1 Anti-CD52 Potent target cell lysis (complement, ADCC) Targets T-, B-, NK cells and monocytes 13 Removing T-cells will reset the autoreactive immune system 14 JS clinical progress Long-term benefit from short-term therapy Ritchie Joint score Day 15 The screen versions of these slides have full details of copyright and acknowledgements 5
6 Lower limit of normal range Isaacs JD, et al., Arthritis Rheum 21;44: Controls.5 Cases Analysis time (days) Isaacs JD, et al., Arthritis Rheum 21;44: Common with CAMPATH-1H Chills, rigors, high fever Urticarial skin rash Hypotension in severe cases Dose-related, minimized with glucocorticoid prophylaxis Cytokine release from NK cells following Fcγ R cross-linking 18 The screen versions of these slides have full details of copyright and acknowledgements 6
7 CYTOKINES CAM PATH-1H CD16 TARGET CELL Wing et al., J Clin Invest 1996;98: NK CELL 19 Short-term benefit Persisting lymphopenia, first-dose reaction No major effect on mortality over the medium term Reconstitution defects may relate to Impaired thymic function 1 Impaired IL7 regulation 2 1 Ponchel F, et al., Blood. 22;1(13): Ponchel F, et al., Arthritis Res Ther. 25;7(1):R Multiple mabs and trials in 199s Double blind randomised controlled trials did not confirm apparent benefits from open studies Depletion a common unwanted effect, even with genetically engineered mabs Some suggestion that efficacy associated with coating of synovial fluid CD4 T-cells Choy E, et al., Arthritis Rheum 1996:52-6 Mason, U, et al., J Rheumatol 22;29: The screen versions of these slides have full details of copyright and acknowledgements 7
8 Wrong disease? Wrong stage of disease? Wrong target (e.g., CD4 vs. CD8 vs. CD28 etc.)? Wrong epitope? Inappropriate dose? Inappropriate duration? Lack of surrogate response markers 22 We are seeking long-term outcomes from brief interventions Treatments not necessarily anti-inflammatory, so there may not be short-term benefit Mechanisms of therapeutic tolerance poorly understood No biomarkers of tolerance induction 23 Rheumatoid arthritis Targeting T-cells Targeting B-cells Costimulation blockade Novel cytokine targets 24 The screen versions of these slides have full details of copyright and acknowledgements 8
9 Autoantibody production Cytokine and chemokine production Antigen presentation to T-cells Co-stimulation of T-cells Synovial structure and organisation Silverman GJ & Carson DA. Arthritis Research & Therapy 23;5 (suppl 4):S1-S6 Panayi GS. Rheumatology 25;44 (suppl2):ii3-ii7 Weyand CM, Seyler TM, Goronzy JJ. Arthritis Research & Therapy 25;7:S9-S12 25 Takemura et al., J Immunol 21;167: Stem cells Pro-B cells Pre-B cells Immature B cells Activated B cells Memory B cells Plasma B cells CD1 Cell surface antigens CD19 CD2 CD24 CD38 CD39 Roitt I et al., Immunology. London, UK: Mosby; 22; Sell S et al., Immunology, Immunopathology, and Immunity. Washington DC: ASM Press; 21; Silverman GJ et al., Arthritis Rheum 23;48: The screen versions of these slides have full details of copyright and acknowledgements 9
10 297-amino acid phosphoprotein (33 37 kda) found on the surface of B cells Highly expressed on B cells but not on stem cells or plasma cells Function unknown Binding of anti-cd2 mab to CD2 does not: Down-modulate expression of CD2 Cause shedding of CD2 from the plasma membrane Good target for cell lysis (CDC, ADCC, apoptosis) 28 Chimeric anti-cd2 mab Murine V-region, human IgG1 C-region Potent B-cell depletion Licensed for use in non-hodgkin s lymphoma Recently licensed for RA in USA License pending in Europe, UK 29 Phase II Study Design and Treatment Groups MTX inadequate responders R A N D O M I Z E D (1g x 2) MTX (>1 mg/wk) N=4 Baseline Edwards JCW, et al., New Engl J Med 24; 35: MTX (>1 mg/wk) N=4 (1g x 2) N=4 (1g x 2) Cytoxan (75 mg x 2) N=41 17 day corticosteroid regimen in all arms 48 weeks 3 The screen versions of these slides have full details of copyright and acknowledgements 1
11 Sex Patient Demographics Female Male MTX (n=4) 8% 2% (n=4) 73% 27% + CTX (n=41) 83% 17% + MTX (n=4) 75% 25% Age (years) Previous DMARDs (mean) Pts receiving concomitant corticosteroids Pts. receiving NSAIDs or COX 2 inhibitors 41% 48% 45% 45% 9% 9% 83% 88% 31 Patients Baseline Disease Characteristics MTX (n=4) (n=4) + CTX (n=41) + MTX (n=4) Disease duration (years) SJC (mean) TJC (mean) RF (median, IU/ml) CRP (mean mg/l) ESR (mean mm/h) DAS % patients ACR Responses at 24 Weeks P= P=.1 76 P=.3 73 P= P=.5 P= P= MTX + CTX + MTX ACR2 ACR5 ACR7 P-values from Fisher s Exact test, comparing the MTX group with each rituximab group 33 The screen versions of these slides have full details of copyright and acknowledgements 11
12 ACR Responses at 48 Weeks 8 7 P<.1 65 % pati ents P=.1 49 P= P=.2 35 P=.3 15 MTX + CTX + MTX ACR2 ACR5 ACR7 P-values from Fisher s Exact test, comparing the MTX group with each rituximab group All withdrawals considered non-responders 34 Edwards JCW, et al., New Engl J Med 24; 35: Circulating B-cell Counts (Median) Median CD19 (Cells x1^3/ul) Time (weeks) MTX R R+CTX R+MTX Edwards JCW, et al., New Engl J Med 24; 35: The screen versions of these slides have full details of copyright and acknowledgements 12
13 2 Median Change (IU/L) Time (Weeks) M TX R R+CTX R+MTX Edwards JCW, et al., New Engl J Med 24; 35: Mean IgG (ng/ml) Lower normal limit Time (Weeks) MTX R R+CTX R+MTX Edwards JCW, et al., New Engl J Med 24; 35: Mean IgM (ng/ml) Lower normal limit Time (Weeks) MTX R R+CTX R+MTX Edwards JCW, et al., New Engl J Med 24; 35: The screen versions of these slides have full details of copyright and acknowledgements 13
14 Dose-ranging Assessment: INternational Clinical Evaluation of in RA (DANCER) Objectives Compare two doses of Study different glucocorticoid pre-medication regimes Emery, P et al., Arthritis Rheum 26; 54: Randomised N= 465 patients 2 x 1 mg Placebo N=149 N=192 2 x 5 mg N=124 All groups received 2 doses 2 weeks apart + no glucocorticoids + IV premedication only a + IV premedication plus oral b + no glucocorticoids + IV premedication only a + IV premedication plus oral b + no glucocorticoids + IV premedication only a + IV premedication plus oral b Primary endpoint: % patients with ACR2 at week 24 Baseline 24 weeks All arms received weekly MTX -25 mg (p.o or patenteral) a Methylprednisolone 1 mg iv on days 1 and 15; b Methylprednisolone 1 mg iv on days 1 & 15 plus oral prednisone, 6 mg/day on days 2 7 and 3 mg on days % patients ACR Responses at 48 Weeks Placebo (n=122) 2x5 mg (n=123) 2x1 mg (n=122) p=.29, p.1 vs. placebo ACR2 ACR5 ACR7 RF +ve patients, ITT population n= The screen versions of these slides have full details of copyright and acknowledgements 14
15 1 st infusion 2 nd infusion Variable Placebo 2x5 mg 2x1 mg Placebo 2x5 mg 2x1 mg Placebo % GC iv % GC iv + po % No difference in ACR2/5 response rate between doses 1 mg methylprednisolone appears to be an appropriate GC premedication regime GC do not contribute to efficacy (data not shown) No difference in AEs between doses (data not shown) 44 QOL Function Damage Responders relapse from 6 months onwards Outstanding questions RhF positive vs. RhF negative RA? Repeated courses? Predictors of relapse? (B-cells, RhF) Long-term safety with repeated courses? 45 The screen versions of these slides have full details of copyright and acknowledgements 15
16 Rheumatoid arthritis Targeting T-cells Targeting B-cells Costimulation blockade Novel cytokine targets 46 APC M HC C D 4 B 7. 1/2 TCR C D 4 L C D 2 8 C TL A -4 T-cell 47 CTLA4 (CD152) IgG1 CTLA4-Ig external Cell Membrane internal Cytotoxic T Lymphocyte-Associated Antigen 4 48 The screen versions of these slides have full details of copyright and acknowledgements 16
17 Patients with Inadequate Response to Methotrexate Abatacept (N = 433) Double-blind Open-label Treated (N = 652) Changes 1 in DMARDs mg/kg Methotrexate continued Placebo (N = 219) allowed Other DMARDs washout Day 1 6 Months 1 Year Screening Randomization Co-primary endpoint ACR2 Co-primary endpoint Physical Function Structural damage Infusions d1, d15, d3 then monthly Kremer JM, et al., Arthritis & Rheumatism 25; 52: Patients with Inadequate Response to Methotrexate Mean Number of tender joints Number of swollen joints Abatacept N = Placebo N = Physical function, HAQ score CRP, mg/dl DAS-28 (ESR) Percent Patients with Erosions > Patients with Inadequate Response to Methotrexate % Responders ^ Primary Endpoint 1 Abatacept (N = 424) Placebo (N = 214) Visit Days p <.1 ^p <.1 p <.5 ITT analysis; All patients who D/C are considered non-responders Infusions d1, d15, d3 then monthly 51 The screen versions of these slides have full details of copyright and acknowledgements 17
18 Patients with Inadequate Response to Methotrexate % Responders Abatacept (N = 424) Placebo (N = 214) ^ Infusions d1, d15, d3 then monthly p <.1 Visit Days ^p <.1 ITT analysis; All patients who D/C are considered non-responders 52 Patients with Inadequate Response to Methotrexate Mean Change from Baseline Abatacept (N = 391) Placebo (N = 195) ^ p <.1 ^ p <.1 Erosion JSN JSN = Joint Space Narrowing Total 53 p <.1 ^ p <.1 p <.5 % Responders (decrease.3) (Decrease in HAQ.3) Patients with Inadequate Response to Methotrexate ^ ITT analysis; All patients who D/C are considered non-responders Infusions d1, d15, d3 then monthly Visit Days Abatacept (N = 424) Placebo (N = 214) 54 The screen versions of these slides have full details of copyright and acknowledgements 18
19 Effective in RA Symptoms and signs Quality of life Function Retardation of joint damage Good safety profile 55 Effective for signs and symptoms, function, QOL, slowing of joint damage More effective when co-administered with methotrexate Good safety record so far Low incidence of anti-globulins Also effective in patients that have failed anti-tnf therapy Combination with anti-tnf (or each other) not advised Current licenses for advanced disease only 56 Rheumatoid arthritis Targeting T-cells Targeting B-cells Costimulation blockade Novel cytokine targets 57 The screen versions of these slides have full details of copyright and acknowledgements 19
20 Physician s global assessment (-1 mm) CRP (mg/dl) Tender joints Patient s global assessment (-1 mm) ESR (mm/hr) Swollen joints placebo 4 mg/kg MRA (tocilizumab) 8 mg/gk MRA (tocilizumab) Every 4 weeks for 3 months No DMARDs allowed Palm score (-1 mm) Week MHAQ score Week Nishimoto N, et al., Arthritis Rheum 24; 5: placebo 4 mg/kg MRA (tocilizumab) 8 mg/kg MRA (tocilizumab) Every 4 weeks for 3 months Nishimoto N, et al., Arthritis Rheum 24; 5: n = 36 MRA (tocilizumab) 8 mg/kg every 4 weeks for 52 weeks vs. standard DMARD therapy (not leflunomide/anti-tnf) Outcomes: ACR response Van der Heijde modified Sharp score Nishimoto N, et al., American College of Rheumatology AGM, 25 6 The screen versions of these slides have full details of copyright and acknowledgements 2
21 At baseline: Mean disease duration, 2.3 years Mean DAS28, 6.9 Mean CRP, 4.8 mg/dl Mean total Sharp score, 3. Nishimoto N, et al., American College of Rheumatology AGM, MRA DMARD Significance Xray progression 2.3 ± ± 11.4 p =.1 ACR2 89% 35% p <.1 ACR5 7% 14% p <.1 ACR7 47% 6% p <.1 AEs 96% 87% SAEs 19% 13% Nishimoto N, et al., American College of Rheumatology AGM, Improves symptoms and signs Functional benefit Retards joint damage No safety signal (?lipids) Currently in phase III 63 The screen versions of these slides have full details of copyright and acknowledgements 21
22 Several mab therapies are licensed, or in trial, for rheumatoid arthritis Target T-cells, B-cells, and cytokines Effective for symptoms and signs, as well as x-ray progression So far they have a good safety record New paradigms for therapy Set new challenges remission now the target Therapeutic tolerance still elusive The screen versions of these slides have full details of copyright and acknowledgements 22
Annual Rheumatology & Therapeutics Review for Organizations & Societies
Annual Rheumatology & Therapeutics Review for Organizations & Societies Comparative Effectiveness Studies of Biologics Learning Objectives Understand the motivation for comparative effectiveness research
More informationNew Evidence reports on presentations given at ACR Improving Radiographic, Clinical, and Patient-Reported Outcomes with Rituximab
New Evidence reports on presentations given at ACR 2009 Improving Radiographic, Clinical, and Patient-Reported Outcomes with Rituximab From ACR 2009: Rituximab Rituximab in combination with methotrexate
More informationRoche data & results at EULAR 2006 Conference call Amsterdam, The Netherlands and Basel, Switzerland Friday, June 23, 2006
We Innovate Healthcare 1 Roche data & results at EULAR 26 Conference call Amsterdam, The Netherlands and Basel, Switzerland Friday, June 23, 26 2 1 Forward-looking statements This presentation contains
More informationEfficacy and Safety of Tocilizumab in the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis
New Evidence reports on presentations given at EULAR 2010 Efficacy and Safety of Tocilizumab in the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis Report on EULAR 2010 presentations
More informationAutoimmune Diseases. Betsy Kirchner CNP The Cleveland Clinic
Autoimmune Diseases Betsy Kirchner CNP The Cleveland Clinic Disclosures (financial) No relevant disclosures Learning Objectives Explain the pathophysiology of autoimmune disease Discuss safe administration
More informationBRIEFING DOCUMENT. human, recombinant fusion protein: extracellular domain of CTLA-4 and Fc domain of human IgG1
BRIEFING DOCUMENT Application Type BLA Submission Number 125118/0 Reviewer Name Team Leader Division Director Established Name (Proposed) Trade Name Applicant Formulation Dosing Regimen Indication Intended
More informationAbatacept (Orencia) for active rheumatoid arthritis. August 2009
Abatacept (Orencia) for active rheumatoid arthritis August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationEfficacy and Safety of Rituximab in the Treatment of Rheumatoid Arthritis and ANCA-associated Vasculitis
New Evidence reports on presentations given at ACR/ARHP 2010 Efficacy and Safety of Rituximab in the Treatment of Rheumatoid Arthritis and ANCA-associated Vasculitis Report on ACR/ARHP 2010 presentations
More informationNew Evidence reports on presentations given at EULAR Safety and Efficacy of Tocilizumab as Monotherapy and in Combination with Methotrexate
New Evidence reports on presentations given at EULAR 2009 Safety and Efficacy of Tocilizumab as Monotherapy and in Combination with Methotrexate Report on EULAR 2009 presentations Tocilizumab inhibits
More informationImmunological Aspect of Ozone in Rheumatic Diseases
Immunological Aspect of Ozone in Rheumatic Diseases Prof. Dr. med. Z. Fahmy Chief Consulting Rheumatologist Augusta Clinic for Rheumatic Diseases And Rehabilitation Bad Kreuznach Germany Rheumatoid arthritis
More informationTreating Rheumatologic Disease in Arizona: Good News, Bad News
Treating Rheumatologic Disease in Arizona: Good News, Bad News Jeffrey R. Lisse, M.D. Ethel P. McChesney Bilby Professor of Medicine Chief, Section of Rheumatology University of Arizona School of Medicine
More informationRheumatoid arthritis
Rheumatoid arthritis 1 Definition Rheumatoid arthritis is one of the most common inflammatory disorders affecting the population worldwide. It is a systemic inflammatory disease which affects not only
More informationLondon, 1 June 2006 Product name: REMICADE Procedure number: Remicade-H-240-II-73-AR SCIENTIFIC DISCUSSION 1/8
London, 1 June 2006 Product name: REMICADE Procedure number: Remicade-H-240-II-73-AR SCIENTIFIC DISCUSSION 1/8 1. Introduction Infliximab is a chimeric human-murine IgG1κ monoclonal antibody, which binds
More informationI n the past, analgesics and nonsteroidal
Rituximab in advanced rheumatoid arthritis Michael Guida BSc, MA Rheumatoid arthritis (RA) continues to have a major impact on public health. Costs to the individual and to the NHS are high, and treatment
More informationJames R. O Dell, M.D. University of Nebraska Medical Center
Not everyone in the world needs a biologic: Lessons from TEAR and RACAT James R. O Dell, M.D. University of Nebraska Medical Center Disclosure Declaration James O Dell, MD Advisory Board for Crescendo,
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC Update on the Treatment of Rheumatoid Arthritis Sabrina Fallavollita MDCM McGill University Canadian Society of Internal Medicine
More informationGSK 165: anti-gm-csf antibody
GSK 165: anti-gm-csf antibody A novel mechanism with potentially differentiated impact on pain in the treatment of Rheumatoid Arthritis 23 October 2018 Cautionary statement regarding forward-looking statements
More informationNew Evidence reports on presentations given at EULAR Tocilizumab for the Treatment of Rheumatoid Arthritis
New Evidence reports on presentations given at EULAR 2012 Tocilizumab for the Treatment of Rheumatoid Arthritis Report on EULAR 2012 presentations Tocilizumab monotherapy is superior to adalimumab monotherapy
More informationNew Evidence reports on presentations given at EULAR Tocilizumab for the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis
New Evidence reports on presentations given at EULAR 2011 Tocilizumab for the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis Report on EULAR 2011 presentations Benefit of continuing
More informationSupplemental Table 1. Key Inclusion Criteria Inclusion Criterion OPTIMA PREMIER 18 years old with RA (per 1987 revised American College of General
Supplemental Table 1. Key Inclusion Criteria Inclusion Criterion OPTIMA PREMIER 18 years old with RA (per 1987 revised American College of General Rheumatology classification criteria) 34 ; erythrocyte
More informationReview B cell targeted therapies Edward Keystone
Available online http://arthritis-research.com/contents/7/s3/s13 Review B cell targeted therapies Edward Keystone Department of Medicine, University of Toronto, Ontario, Canada Corresponding author: Edward
More informationRheumatology journal club October 20, 2017 Presented by: Matthew Stoll MD,PhD,PSCS
Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis (Mease et al., 2017) Rheumatology journal club October 20,
More informationNew Evidence reports on presentations given at EULAR Rituximab for the Treatment of Rheumatoid Arthritis and Vasculitis
New Evidence reports on presentations given at EULAR 2011 Rituximab for the Treatment of Rheumatoid Arthritis and Vasculitis Report on EULAR 2011 presentations Anti-TNF failure and response to rituximab
More informationOrencia (abatacept) for Rheumatoid Arthritis. Media backgrounder
Orencia (abatacept) for Rheumatoid Arthritis Media backgrounder What is Orencia (abatacept)? Orencia (abatacept) is the first biologic agent to be available in both an intravenous (IV) and a self-injectable,
More informationTreatment of Rheumatoid Arthritis: The Past, the Present and the Future
Treatment of Rheumatoid Arthritis: The Past, the Present and the Future Lai-Ling Winchow FCP(SA) Cert Rheum(SA) Chris Hani Baragwanath Academic Hospital University of the Witwatersrand Outline of presentation
More informationRheumatoid Arthritis. Improving Outcomes in RA: Three Pillars. RA: Chronic Joint Destruction and Disability What We Try to Prevent
Rheumatoid Arthritis Modern Management of Common Problems in Rheumatology: Rheumatoid Arthritis Jonathan Graf, M.D. Associate Professor of Medicine, UCSF Division of Rheumatology, SFGH Director, UCSF Rheumatoid
More information1.0 Abstract. Title. Keywords. Rationale and Background
1.0 Abstract Title A Prospective, Multi-Center Study in Rheumatoid Arthritis Patients on Adalimumab to Evaluate its Effect on Synovitis Using Ultrasonography in an Egyptian Population Keywords Synovitis
More informationSynopsis (C0524T12 GO LIVE)
Protocol: EudraCT No.: 2005-003232-21 Title of the study: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFα Monoclonal Antibody, Administered Intravenously,
More informationScottish Medicines Consortium
Scottish Medicines Consortium abatacept, 250mg powder for concentrate for solution (Orencia ) No. (400/07) Bristol Myers Squibb Pharmaceuticals Ltd 10 August 2007 The Scottish Medicines Consortium has
More informationAUTOIMMUNITY CLINICAL CORRELATES
AUTOIMMUNITY CLINICAL CORRELATES Pamela E. Prete, MD, FACP, FACR Section Chief, Rheumatology VA Healthcare System, Long Beach, CA Professor of Medicine, Emeritus University of California, Irvine Colonel
More informationRheumatoid Arthritis: When to Start and when to Stop anti-tnf Therapy
Rheumatoid Arthritis: When to Start and when to Stop anti-tnf Therapy [ Cuando iniciar o detener la tx anti-tnf?] Asociacion Costatarricense Medicina Interna August 7, 2015 Arthur Weinstein, MD, FACP,
More informationAUTOIMMUNITY TOLERANCE TO SELF
AUTOIMMUNITY CLINICAL CORRELATES Pamela E. Prete, MD, FACP, FACR Section Chief, Rheumatology VA Healthcare System, Long Beach, CA Professor of Medicine, Emeritus University of California, Irvine Colonel
More informationEtiology: Pathogenesis Clinical manifestation Investigation Treatment Prognosis
Etiology: Pathogenesis Clinical manifestation Investigation Treatment Prognosis JIA is the most common rheumatic disease in childhood and a major cause of chronic disability. Etiology: Unknown, but may
More informationMAF Shalaby Prof. Rheumatology Al Azhar University, Cairo, Egypt.
MAF Shalaby Prof. Rheumatology Al Azhar University, Cairo, Egypt. AUTOIMMUNE DISEASE RA SLE VASCULITIS RELAPSING POLYCHONDRITIS SS DM/PM SJOGREN S SYNDROME RHEUMATOID ARTHRITIS Classically immune mediated
More information2.0 Synopsis. Adalimumab DE019 OLE (5-year) Clinical Study Report Amendment 1 R&D/06/095. (For National Authority Use Only)
2.0 Synopsis Abbott Laboratories Name of Study Drug: Humira Name of Active Ingredient: Adalimumab Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority Use Only) Title
More informationMMS Pharmacology Lecture 2. Antirheumatic drugs. Dr Sura Al Zoubi
MMS Pharmacology Lecture 2 Antirheumatic drugs Dr Sura Al Zoubi Revision Rheumatoid Arthritis Definition (RA): is the most common systemic inflammatory disease characterized by symmetrical inflammation
More informationORENCIA (abatacept) Demonstrates Comparable Efficacy to Humira ( adalimumab
ORENCIA (abatacept) Demonstrates Comparable Efficacy to Humira (adalimumab) in Patients with Moderate to Severe Rheumatoid Arthritis in First Head-to-Head Study of These Agents ORENCIA demonstrated comparable
More informationAdult-onset Still s disease a polygenic autoinflammatory disease
Adult-onset Still s disease a polygenic autoinflammatory disease Tom Pettersson, MD, PhD University of Helsinki and Helsinki University Central Hospital IL-1 mediated diseases past present and future Såstaholm
More informationSynopsis (C0743T10) CNTO 1275 Module 5.3 C0743T10. Associated with Module 5.3 of the Dossier
Module 5.3 Protocol: EudraCT No.: 2005-003525-92 Title of the study: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of, a Fully Human Anti-IL-12 Monoclonal Antibody, Administered
More informationMabThera (rituximab) NICE STA Submission
MabThera (rituximab) NICE STA Submission ACHIEVING CLINICAL EXCELLENCE IN THE TREATMENT OF RHEUMATOID ARTHRITIS Roche Submission to the National Institute for Health and Clinical Excellence 21 st November
More informationChapter 6. Teng YKO Tekstra J Breedveld FC Lafeber F Bijlsma JWJ van Laar JM. Submitted
Rituximab fixed retreatment versus on-demand retreatment in refractory rheumatoid arthritis Comparison of two B-cell depleting treatment strategies Teng YKO Tekstra J Breedveld FC Lafeber F Bijlsma JWJ
More informationHorizon Scanning Research & Intelligence Centre. Baricitinib for moderate to severe rheumatoid arthritis. May 2015 SUMMARY NIHR HSRIC ID: 5270
May 2015 Horizon Scanning Research & Intelligence Centre Baricitinib for moderate to severe rheumatoid arthritis SUMMARY NIHR HSRIC ID: 5270 This briefing is based on information available at the time
More information1 Executive summary. Background
1 Executive summary Background Rheumatoid Arthritis (RA) is the most common inflammatory polyarthropathy in the UK affecting between.5% and 1% of the population. The mainstay of RA treatment interventions
More informationISSN: (Print) (Online) Journal homepage:
mabs ISSN: 1942-0862 (Print) 1942-0870 (Online) Journal homepage: https://www.tandfonline.com/loi/kmab20 Certolizumab Pegol Niti Goel & Sue Stephens To cite this article: Niti Goel & Sue Stephens (2010)
More informationIndividual Study Table Referring to Part of Dossier: Use Only) Name of Study Drug:
2.0 Synopsis AbbVie Inc. Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: Adalimumab (Humira ) Page: Name of Active Ingredient: Adalimumab
More informationB cells: a fundamental role in the pathogenesis of rheumatoid arthritis?
Rheumatology 2005;44(Suppl. 2):ii3 ii7 B cells: a fundamental role in the pathogenesis of rheumatoid arthritis? doi:10.1093/rheumatology/keh616 The role of T cells in the pathogenesis of RA is well established,
More informationHorizon Scanning Technology Summary. Abatacept (Orencia) for juvenile idiopathic arthritis. National Horizon Scanning Centre.
Horizon Scanning Technology Summary National Horizon Scanning Centre Abatacept (Orencia) for juvenile idiopathic arthritis June 2007 This technology summary is based on information available at the time
More informationPatient #1. Rheumatoid Arthritis. Rheumatoid Arthritis. 45 y/o female Morning stiffness in her joints >1 hour
Patient #1 Rheumatoid Arthritis Essentials For The Family Medicine Physician 45 y/o female Morning stiffness in her joints >1 hour Hands, Wrists, Knees, Ankles, Feet Polyarticular, symmetrical swelling
More informationHorizon Scanning Centre November Secukinumab for active and progressive psoriatic arthritis. SUMMARY NIHR HSC ID: 5330
Horizon Scanning Centre November 2012 Secukinumab for active and progressive psoriatic arthritis. SUMMARY NIHR HSC ID: 5330 Secukinumab is a high-affinity fully human monoclonal antibody that antagonises
More informationPRODUCT INFORMATION HUMIRA
NAME OF THE MEDICINE Adalimumab (rch) DESCRIPTION PRODUCT INFORMATION HUMIRA (adalimumab) is a recombinant human immunoglobulin (IgG1) monoclonal antibody containing only human peptide sequences. was created
More informationRheumatoid Arthritis Update
Rheumatoid Arthritis Update Beth Valashinas, DO, FACOI, FACR Disclosures Speaker for AbbVie Pharmaceuticals Learning Objectives Upon completion of this session, participants should be able to discuss:
More informationMedical Management of Rheumatoid Arthritis (RA)
Medical Management of Rheumatoid Arthritis (RA) Dr Lee-Suan Teh Rheumatologist Royal Blackburn Hospital Educational objectives ABC Appreciate the epidemiology of RA Be able to diagnosis of RA Competent
More informationDrug Class Review on Targeted Immune Modulators
Drug Class Review on Targeted Immune Modulators Final Report Update 1 Evidence Tables January 2007 Original Report Date: December 2005 A literature scan of this topic is done periodically The purpose of
More informationRheumatoid Arthritis. By: Hadi Esmaily (PharmD., BCCP, MBA) Department of Clinical Pharmacy, Shahid Beheshti Medical University
Rheumatoid Arthritis By: Hadi Esmaily (PharmD., BCCP, MBA) Department of Clinical Pharmacy, Shahid Beheshti Medical University Introduction RA is a Chronic, Systemic, Inflammatory disorder of unknown etiology
More informationRheumatoid Arthritis. Module III
Rheumatoid Arthritis Module III Management: Biological disease modifying anti-rheumatic drugs, glucocorticoids and special situations (pregnancy & lactation) Dr Ved Chaturvedi MD, DM Senior Consultant
More informationcorticosteroids. The effort to slow the progression of RA includes diseasemodifying (DMARDs), which include gold salts,
Rituximab for Patients with Refractory Rheumatoid Arthritis Patty Ghazvini, PharmD, Angela Singh, PharmD, Phillip Treadwell, PharmD, Marlon Honeywell, PharmD, and Natosha Canty, MD Dr. Ghazvini and Dr.
More informationREMICADE POWDER FOR INJECTION
REMICADE POWDER FOR INJECTION Infliximab PRODUCT INFORMATION NAME OF THE MEDICINE Infliximab Powder for Injection DESCRIPTION Each vial of REMICADE contains infliximab 100 mg. REMICADE Powder for Injection
More informationPRODUCT INFORMATION. ORENCIA (abatacept) (LYOPHILIZED POWDER FOR IV INFUSION) (SOLUTION FOR SUBCUTANEOUS ADMINISTRATION)
PRODUCT INFORMATION ORENCIA (abatacept) (LYOPHILIZED POWDER FOR IV INFUSION) (SOLUTION FOR SUBCUTANEOUS ADMINISTRATION) NAME OF THE MEDICINE ORENCIA (abatacept (rch)) ORENCIA (abatacept (rch)). Abatacept
More informationRheumatoid Arthritis. Manish Relan, MD FACP RhMSUS Arthritis & Rheumatology Care Center. Jacksonville, FL (904)
Rheumatoid Arthritis Manish Relan, MD FACP RhMSUS Arthritis & Rheumatology Care Center. Jacksonville, FL (904) 503-6999. 1 Disclosures Speaker Bureau: Abbvie 2 Objectives Better understand the pathophysiology
More informationUsing ENBREL to Treat Rheumatoid and Psoriatic Arthritis
Using ENBREL to Treat Rheumatoid and Psoriatic Arthritis Writing White Papers class Bellevue Community College TABLE OF CONTENTS TABLE OF CONTENTS...2 OVERVIEW...3 RHEUMATOID ARTHRITIS... 3 JUVENILE RHEUMATOID
More informationof 0.20) and Health assessment questionnaire disability index (HAQ-DI) (r partial
IL-6 receptor inhibition modulates type III collagen and C-reactive protein degradation in rheumatoid arthritis patients with an inadequate response to anti-tumour necrosis factor therapy: analysis of
More informationAntirheumatic drugs. Rheumatic Arthritis (RA)
Antirheumatic drugs Rheumatic Arthritis (RA) Disease Modifying Antirheumatic drugs (DMARDs) DMARDs are used in the treatment of rheumatic arthritis RA and have been shown to slow the course of the disease,
More informationTreat - to - Target Pathway Commissioning Chronic and Complex Care MIDLANDS RHEUMATOLOGY & MUSCULOSKELETAL (MSK) COMMISSIONING NETWORK
Treat - to - Target Pathway Commissioning Chronic and Complex Care MIDLANDS RHEUMATOLOGY & MUSCULOSKELETAL (MSK) COMMISSIONING NETWORK Dr Bruce Kirkham Consultant Rheumatologist Guy s & St Thomas NHS Foundation
More informationCharité - University Hospital, Free University and Humboldt University of Berlin, Berlin, Germany; 2 Sanofi Genzyme, Bridgewater, NJ, USA; 3
Efficacy and Safety of Sarilumab Versus Adalimumab in a Phase 3, Randomized, Double-blind, Monotherapy Study in Patients With Active Rheumatoid Arthritis With Intolerance or Inadequate Response to Methotrexate
More informationRequirements in the Development of an Autoimmune Disease Amino Acids in the Shared Epitope
+ T cell MHC/self-peptide MHC/Vβ Induction of + T H 1 mediated autoimmunity: A paradigm for the pathogenesis of rheumatoid arthritis, multiple sclerosis and type I diabetes APC Activated autoreactive +
More information2.0 Synopsis. Adalimumab (HUMIRA ) W Clinical Study Report R&D/15/0629. Individual Study Table Referring to Part of Dossier: Volume:
2.0 Synopsis AbbVie Inc. Name of Study Drug: Adalimumab / HUMIRA Name of Active Ingredient: Adalimumab Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority Use Only)
More informationTuberculosis and Biologic Therapies: Risk and Prevention
Tuberculosis and Biologic Therapies: Risk and Prevention Kevin L. Winthrop, MD, MPH Associate Professor, Divisions of Infectious Diseases, Public Health and Preventive Medicine Oregon Health & Science
More informationBringing the clinical experience with anakinra to the patient
Rheumatology 2003;42(Suppl. 2):ii36 ii40 doi:10.1093/rheumatology/keg331, available online at www.rheumatology.oupjournals.org Bringing the clinical experience with anakinra to the patient S. B. Cohen
More informationGuideline on clinical investigation of medicinal products for the treatment of rheumatoid arthritis
14 December 2017 CPMP/EWP/556/95 Rev. 2 Committee for Medicinal Products for Human Use (CHMP) Guideline on clinical investigation of medicinal products for the treatment of Draft Agreed by Rheumatology-Immunology
More informationDr Daniel Ching. Rheumatology Therapeutic Clinical Trials Centre Timaru
Dr Daniel Ching Rheumatology Therapeutic Clinical Trials Centre Timaru Therapeutic Advances in Rheumatology GP CME Meeting, Dunedin, 18.08.2013 Dr Daniel Ching, MB FRCP FRACP Consultant Rheumatologist,
More informationAmino acid sequences in the β chain HLA- DRB*0401 molecules dictate susceptibility to RA Amino Acids in the Shared Epitope
MHC/self-peptide MHC/Vβ TCR Vβx + Vβx T cell Induction of + TH1 mediated autoimmunity: A paradigm for the pathogenesis of rheumatoid arthritis, multiple sclerosis and APC type I diabetes TCR Vβx Activated
More informationThis is a repository copy of Targeting interleukin-6 in rheumatoid arthritis.
This is a repository copy of Targeting interleukin-6 in rheumatoid arthritis. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/85075/ Version: Accepted Version Article: Md
More informationTreatment of psoria.c arthri.s: Guidelines and beyond. Pascal RICHETTE Hôpital Lariboisière, Paris
Treatment of psoria.c arthri.s: Guidelines and beyond Pascal RICHETTE Hôpital Lariboisière, Paris The pa.ent: a 37 year- old man, with a history of psoriasis for 10 years Past history: - Dyslipidemia Current
More informationEarly and late responses to tocilizumab in RA / T. Dörner et al. SUPPLEMENTARY APPENDIX. Supplementary appendix 1: Selection criteria
SUPPLEMENTARY APPENDIX Supplementary appendix 1: Selection criteria Inclusion criteria included Active rheumatoid arthritis (RA) of 6 months duration at baseline, Disease Activity Score using 28 joints
More informationFigure 1. Study flow diagram. Reasons for withdrawal during the extension phase are included in the flow diagram. 508 patients enrolled and randomized
508 patients enrolled and randomized 126 assigned to sequential monotherapy (group 1) 121 assigned to step-up combination therapy (group 2) 133 assigned to initial combination therapy with prednisone (group
More informationThe Rheumatoid Hand Deformities & Management. Dr. Anirudh Sharma Resident Department of Orthopedics
+ The Rheumatoid Hand Deformities & Management Dr. Anirudh Sharma Resident Department of Orthopedics + Why is Rheumatoid Arthritis important? + RA is a very debilitating disease median life expectancy
More informationIntroduction ORIGINAL ARTICLE
Mod Rheumatol (2007) 17:28 32 Japan College of Rheumatology 2007 DOI 10.1007/s10165-006-0532-0 ORIGINAL ARTICLE Hisashi Yamanaka Yoshiya Tanaka Naoya Sekiguchi Eisuke Inoue Kazuyoshi Saito Hideto Kameda
More informationUnderstanding Myositis Medications
Understanding Myositis Medications 2015 TMA Annual Patient Conference Orlando, Florida Chester V. Oddis, MD University of Pittsburgh Director, Myositis Center Disclosures Mallinckrodt: Research Grant Genentech:
More information10/28/2013. Disclosures. Objectives. Background. Study Design. Key Inclusion Criteria
Randomization (1:1:1:1) /28/13 Tocilizumab in Combination Therapy and Monotherapy Versus Methotrexate in Methotrexate-Naive Patients With Early Rheumatoid Arthritis: Clinical and Radiographic Outcomes
More informationHow to write & publish a scientific paper Basic Concepts & Methods
INAYA MEDICAL COLLEGE (IMC) NMT 472 - LECTURE 5 How to write & publish a scientific paper Basic Concepts & Methods DR. MOHAMMED MOSTAFA EMAM I. Before start writing II.Writing the article III.Making the
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,700 108,500 1.7 M Open access books available International authors and editors Downloads Our
More informationEarly synovitis clinics
Early synovitis clinics Jeremy Jones MD FRACP FAFRM Consultant Rheumatologist, Llandudno General Hospital Honorary Research Fellow School of Sport, Health and Exercise Sciences Bangor University RA medication
More informationNEW ZEALAND DATA SHEET
NEW ZEALAND DATA SHEET SIMPONI Solution for Injection in a pre-filled syringe Solution for Injection in a pre-filled pen, SmartJect NAME OF MEDICINE SIMPONI Solution for Injection in a pre-filled syringe
More informationThe Hospital for Sick Children Technology Assessment at SickKids (TASK)
The Hospital for Sick Children Technology Assessment at SickKids (TASK) THE USE OF BIOLOGIC RESPONSE MODIFIERS IN POLYARTICULAR-COURSE JUVENILE IDIOPATHIC ARTHRITIS Report No. 2010-01 Date: January 11,
More informationGolimumab: In Combination with Methotrexate as Once Monthly Treatment for Moderate to Severe Rheumatoid Arthritis
Clinical Medicine Reviews in Therapeutics Review Golimumab: In Combination with Methotrexate as Once Monthly Treatment for Moderate to Severe Rheumatoid Arthritis Lauren Keyser McCluggage 1 and Kelly Michelle
More informationRituximab, recombinant for intravenous infusion (CAS registry number: ).
MABTHERA Rituximab, recombinant for intravenous infusion (CAS registry number: 174722-31-7). WARNING Use of MABTHERA may be associated with an increased risk of progressive multifocal leukoencephalopathy
More informationCertolizumab pegol (Cimzia) for psoriatic arthritis second line
Certolizumab pegol (Cimzia) for psoriatic arthritis second line This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationCriteria Inclusion criteria Exclusion criteria. despite treatment with csdmards, NSAIDs, and/or previous anti-tnf therapy and/or
Supplementary Material Table S1 Eligibility criteria (PICOS) for the SLR Criteria Inclusion criteria Exclusion criteria Population Adults (aged 18 years) with active PsA despite treatment with csdmards,
More informationBiologic therapy for Rheumatoid arthritis. Paul Etau Ekwom Physician and Rheumatologist
Biologic therapy for Rheumatoid arthritis Paul Etau Ekwom Physician and Rheumatologist Objectives Case presentation of patient with rheumatoid arthritis on a biologic therapy. Discuss biologic therapy
More informationPros and Cons of Combination MTX+ Biologics vs Monotherapy with Biologics: the place of immunogenicity
Pros and Cons of Combination MTX+ Biologics vs Monotherapy with Biologics: the place of immunogenicity Daniel E Furst MD University of California in Los Angeles University of Washington University of Florence
More informationTechnology appraisal guidance Published: 25 August 2010 nice.org.uk/guidance/ta195
Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor Technology appraisal guidance Published: 25 August 2010 nice.org.uk/guidance/ta195
More informationEXECUTIVE SUMMARY. Date of Report: 25-Mar Database as of: 05-Mar-2008
EXECUTIVE SUMMARY Date of Report: 25-Mar-2008 Database as of: 05-Mar-2008 Title of Study: Protocol : A Phase II, Multi-center, Randomized, Double-Blind, Placebo Controlled, Dose-Response Study to Evaluate
More informationRheumatoid Arthritis
Rheumatoid Arthritis Rheumatoid arthritis (RA) is an autoimmune disease that causes chronic inflammation of the joints. Autoimmune diseases are illnesses that occur when the body's tissues are mistakenly
More informationUNFOLDING NATURE S ORIGAMI: MEDICAL TREATMENT OF TAKAYASU ARTERITIS AND GIANT CELL ARTERITIS
UNFOLDING NATURE S ORIGAMI: MEDICAL TREATMENT OF TAKAYASU ARTERITIS AND GIANT CELL ARTERITIS CanVasc meeting Montreal Nov 22 2012 Patrick Liang Service de rhumatologie Centre Hospitalier Universitaire
More informationCoverage Criteria: Express Scripts, Inc. monograph dated 12/15/ months or as otherwise noted by indication
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Kineret (anakinra subcutaneous injection) Commercial HMO/PPO/CDHP
More informationcertolizumab pegol (Cimzia )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: 01/19/2016. ClinicalTrials.gov ID: NCT
ClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: 01/19/2016 ClinicalTrials.gov ID: NCT00595413 Study Identification Unique Protocol ID: 27905 Brief Title: Atacicept
More informationSIGNIFICANCE OF ELEVATED INTERLEUKIN-6 LEVEL IN JUVENILE RHEUMATOID ARTHRITIS PATIENTS
SIGNIFICANCE OF ELEVATED INTERLEUKIN-6 LEVEL IN JUVENILE RHEUMATOID ARTHRITIS PATIENTS Essam Tewfik Attwa and S. Al-Beltagy* Rheumatology & Rehabilitation Department, Zagazig University Faculty of Medicine
More informationEthnic Differences in PK and PD of Anti-Rheumatic Drugs
2010 China-Japan Symposium on Global Clinical Trials and Ethnic Factors May 28 th, 2010, JW Marriott Hotel Beijing Ethnic Differences in PK and PD of Anti-Rheumatic Drugs Shinichi Kawai, MD, PhD Division
More information